ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Affiris Expands Patent Portfolio For Alzheimer¹s Therapies
Affiris GmbH has secured another Europe-wide
patent for an innovative method of treating Alzheimer's disease. This new
blood-cleansing method is similar to dialysis and is designed to reduce
the
amount of harmful protein deposits in the brain. It is based on the
AFFITOME
technology established by Affiris, which was patented in October 2007 for
an
Alzheimer's vaccine. The use of this technology to cleanse the blood
underlines the leading international role that Affiris plays in the
development of innovative Alzheimer's treatments, a role that has been
underpinned financially by investment from the German company MIG-Fonds.
Affiris GmbH, which is based in Vienna, Austria, today announced that it
has
been granted a Europe-wide patent for a new method of reducing the amount
of
harmful protein deposits (beta-amyloid) in the brains of Alzheimer's
patients. A key feature of this method is the cleansing of the patient¹s
blood (apheresis). This enables the targeted removal of the proteins that
cause the accumulation of deposits in the brain, and therefore the onset
of
the disease.
Dr. Walter Schmidt, CEO of Affiris GmbH, comments on the importance of the
patent: "Affiris already has its first proprietary vaccine for the
treatment
of Alzheimer's in clinical testing and a second is set to follow later
this
year. Our apheresis is an alternative approach to the treatment of
Alzheimer's and complements our vaccine strategy. We have therefore
successfully advanced our business plans for this indication and we will
now
harness the potential of AFFITOME technology for the development of
further
therapies. In accordance with our corporate strategy, we will focus on
medical needs that have not yet been adequately addressed but offer
significant market potential, such as Alzheimer's or Atherosclerosis."
The recently patented process involves fixing receptor molecules onto a
carrier material and using them to bind the beta-amyloid that can lead to
the formation of plaques in the brains of Alzheimer's patients. The fixed
receptor molecules from Affiris, which can help reduce the amount of
beta-amyloid present in the blood (serum), can be deployed during
hemodialysis.
What may, at first glance, seem a somewhat unusual approach  using
hemodialysis to achieve therapeutic effects in the brain  is actually
based
on sound science, as Dr. Schmidt explains:Â "The beta-amyloid molecules
that
lead to the formation of plaques can penetrate the blood-brain barrier via
directed transport. As a result, their concentration in the brain
correlates
directly to their concentration in the blood. If we can reduce
beta-amyloid
concentrations in the blood  as our apheresis permits us to Â
beta-amyloid
is then transported out of the brain and into the bloodstream until the
concentration is balanced again. Consequently, removing beta-amyloid from
the blood gradually reduces the concentration of beta-amyloid and its
fragments in the brain."
The key to this is ensuring that the receptor molecules have the correct
binding properties. Affiris AFFITOME technology delivers these properties
by
enabling scientists to define and generate molecules with very specific
binding characteristics. This technology also offers a significant
advantage
in the development of vaccines against human rogue proteins. In this case,
it means that autoimmune reactions can be avoided, as Affiris has already
proven with its first Alzheimer's vaccine.
Michael Motschmann, Senior Fund Manager at MIG-Fonds, explains his views
on
AFFITOME technology: "AFFITOME technology has already demonstrated its
potential in the Alzheimer's vaccine that is currently undergoing clinical
testing. As investors, we will now work with Affiris to continue
developing
this potential for further medical indications. This will underpin the
company's leading role in the development of innovative Alzheimer's
therapies with a diversified pipeline."
About AFFiRiS GmbH (as at February 2008)
AFFiRiS GmbH develops peptide-based vaccines for the treatment of
Alzheimer's disease, atherosclerosis and other serious diseases. The
company
has established its AFFITOME platform technologies. It employs 30 highly
qualified members of staff on 600 sqm of rented laboratory facilities at
the
Campus Vienna Biocenter
AFFITOPE and AFFITOME are registered trademarks of Affiris GmbH.
AFFiRiS GmbH
About MIG-Fonds
The participation of MIG Verwaltungs AG in Affiris GmbH represents the
continuation of a tried-and-tested approach. Investment is only made in
selected companies in Germany and Austria after their viability has been
thoroughly audited. Their innovative, high-potential products and the
entrepreneurial skills of their management teams are both key. MIG
Verwaltungs AG is supported by Alfred Wieder AG. This specialist in
venture
capital is experienced in the sale of holdings and is therefore the first
point of contact for any potential investors.
MIG-Fonds
Affiris extinde portofoliul de brevet pentru Alzheimer ? i terapii - Affiris Expands Patent Portfolio For Alzheimer¹s Therapies - articole medicale engleza - startsanatate